Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Increased to $23.00 by Analysts at Jefferies Financial Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price hoisted by Jefferies Financial Group from $19.00 to $23.00 in a research note issued to investors on Thursday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

TEVA has been the subject of several other research reports. StockNews.com lowered shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating in a research report on Monday, May 20th. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a buy rating in a research note on Thursday, May 30th. Piper Sandler reissued an overweight rating and set a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an underweight rating to a neutral rating and set a $14.00 price objective for the company in a research note on Friday, March 8th. Finally, Barclays raised their target price on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an overweight rating in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $17.00.

Teva Pharmaceutical Industries Stock Up 0.1 %

TEVA stock opened at $16.27 on Thursday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 12 month low of $7.42 and a 12 month high of $17.69. The firm has a market capitalization of $18.43 billion, a PE ratio of -39.68, a P/E/G ratio of 1.58 and a beta of 0.91. The company’s 50 day simple moving average is $15.92 and its 200-day simple moving average is $13.61.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. Equities analysts expect that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares in the company, valued at approximately $16,706,430. The disclosure for this sale can be found here. Insiders sold a total of 549,719 shares of company stock valued at $9,353,736 over the last 90 days. 0.55% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently added to or reduced their stakes in the business. New Covenant Trust Company N.A. bought a new position in Teva Pharmaceutical Industries during the first quarter worth about $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $30,000. Blue Trust Inc. grew its position in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after acquiring an additional 2,180 shares during the period. Industrial Alliance Investment Management Inc. acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. Finally, Psagot Value Holdings Ltd. Israel bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $57,000. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.